Skip to main content
Premium Trial:

Request an Annual Quote

Celera Diagnostics, Merck Form Research Collaboration

NEW YORK, Oct. 20 (GenomeWeb News) - Celera Diagnostics said today that it has formed a research collaboration with Rosetta Inpharmatics, and its parent company Merck, to identify and validate genetic markers that can be used to develop tests and treatments for select cancers.


Under the arrangement, Celera Diagnostics will ahve access to certain Rosetta gene expression data and intellectual property. Merck will have access to certain research data from Celera Diagnostics that can be applied toward cancer drug development.


The partnership is initally focused on breast cancer, but may be expanded to include other malignancies.  Additional terms of the deal were not disclosed.


"Celera Diagnostics has accessed two large collections of tissue samples to support its ongoing disease association studies in breast cancer," Tom White, CSO of Celera Diagnostics, said in a statement. "We believe our studies, coupled with Merck's groundbreaking work, could lead to prognostic tests suitable for routine clinical practice, as well as the identification of novel drug targets for cancer treatment."

The Scan

Genome Sequences Reveal Range Mutations in Induced Pluripotent Stem Cells

Researchers in Nature Genetics detect somatic mutation variation across iPSCs generated from blood or skin fibroblast cell sources, along with selection for BCOR gene mutations.

Researchers Reprogram Plant Roots With Synthetic Genetic Circuit Strategy

Root gene expression was altered with the help of genetic circuits built around a series of synthetic transcriptional regulators in the Nicotiana benthamiana plant in a Science paper.

Infectious Disease Tracking Study Compares Genome Sequencing Approaches

Researchers in BMC Genomics see advantages for capture-based Illumina sequencing and amplicon-based sequencing on the Nanopore instrument, depending on the situation or samples available.

LINE-1 Linked to Premature Aging Conditions

Researchers report in Science Translational Medicine that the accumulation of LINE-1 RNA contributes to premature aging conditions and that symptoms can be improved by targeting them.